The table below shows Aquestive Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Revenue
$44.55M
$57.56M
$50.58M
$47.68M
$50.83M
$45.85M
Cost of revenue
$18.55M
$17.87M
$20.83M
$19.39M
-
$12.96M
Gross profit
-
-
-
-
-
-
R&D
$17.19M
$20.28M
$13.10M
$17.48M
$17.05M
$19.89M
SG&A
AQST annual revenue (10-K history)
Aquestive Therapeutics, Inc. reported annual revenue of $44.55M for fiscal year 2025. That is down 22.6% from $57.56M in fiscal 2024. Over the 9 fiscal years shown, annual revenue declined from $66.92M (FY 2017) to $44.55M. Figures come from the company's audited annual reports as filed with the SEC.